Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal dominant neuromuscular disorder that is characterized by extreme variability in symptoms, with females being less severely affected than males and presenting a higher proportion of asymptomatic carriers. The sex-related factors involved in the disease are not known. Here, we have utilized myoblasts isolated from FSHD patients (FSHD myoblasts) to investigate the effect of estrogens on muscle properties. Our results demonstrated that estrogens counteract the differentiation impairment of FSHD myoblasts without affecting cell proliferation or survival. Estrogen effects are mediated by estrogen receptor β (ERβ), which reduces chromatin occupancy and transcriptional activity of double homeobox 4 (DUX4), a protein whose aberrant expression has been implicated in FSHD pathogenesis. During myoblast differentiation, we observed that the levels and activity of DUX4 increased progressively and were associated with its enhanced recruitment in the nucleus. ERβ interfered with this recruitment by relocalizing DUX4 in the cytoplasm. This work identifies estrogens as a potential disease modifier that underlie sex-related differences in FSHD by protecting against myoblast differentiation impairments in this disease.
Emanuela Teveroni, Marsha Pellegrino, Sabrina Sacconi, Patrizia Calandra, Isabella Cascino, Stefano Farioli-Vecchioli, Angela Puma, Matteo Garibaldi, Roberta Morosetti, Giorgio Tasca, Enzo Ricci, Carlo Pietro Trevisan, Giuliana Galluzzi, Alfredo Pontecorvi, Marco Crescenzi, Giancarlo Deidda, Fabiola Moretti
Title and authors | Publication | Year |
---|---|---|
The Unexplored Role of Connexin Hemichannels in Promoting Facioscapulohumeral Muscular Dystrophy Progression
Díaz-Ubilla M, Retamal MA |
International Journal of Molecular Sciences | 2025 |
Engineered FSHD mutations results in D4Z4 heterochromatin disruption and feedforward DUX4 network activation
Kong X, Nguyen NV, Li Y, Sakr JS, Williams K, Sharifi S, Chau J, Bayrakci A, Mizuno S, Takahashi S, Kiyono T, Tawil R, Mortazavi A, Yokomori K |
iScience | 2024 |
Extract of Curculigo capitulata Ameliorates Postmenopausal Osteoporosis by Promoting Osteoblast Proliferation and Differentiation
Wang Y, Wang X, Wang K, Qin W, Li N |
Cells | 2024 |
The double homeodomain protein DUX4c is associated with regenerating muscle fibers and RNA-binding proteins.
Claus C, Slavin M, Ansseau E, Lancelot C, Bah K, Lassche S, Fiévet M, Greco A, Tomaiuolo S, Tassin A, Dudome V, Kusters B, Declèves AE, Laoudj-Chenivesse D, van Engelen BGM, Nonclercq D, Belayew A, Kalisman N, Coppée F |
Skeletal Muscle | 2023 |
Abstracts of the 2023 Padua Days of Muscle and Mobility Medicine (2023Pdm3) to be held March 29 - April 1 at the Galileian Academy of Padua and at the Petrarca Hotel, Thermae of Euganean Hills, Padua, Italy
Zampieri S, Narici MV, Gargiulo P, Carraro U |
European Journal of Translational Myology | 2023 |
WDR5 is required for DUX4 expression and its pathological effects in FSHD muscular dystrophy.
Mocciaro E, Giambruno R, Micheloni S, Cernilogar FM, Andolfo A, Consonni C, Pannese M, Ferri G, Runfola V, Schotta G, Gabellini D |
Nucleic Acids Research | 2023 |
Molecular and Phenotypic Changes in FLExDUX4 Mice
Murphy K, Zhang A, Bittel AJ, Chen YW |
Journal of Personalized Medicine | 2023 |
2023 Padua Days of Muscle and Mobility Medicine: post meeting book of abstracts
Zampieri S, Bersch I, Kern H, Sarabon N, Rosati R, LeBrasseur NK, Leeuwenburgh C, Carraro U |
European Journal of Translational Myology | 2023 |
The FSHD muscle-blood biomarker: a circulating transcriptomic biomarker for clinical severity in facioscapulohumeral muscular dystrophy.
Banerji CRS, Greco A, Joosten LAB, van Engelen BGM, Zammit PS |
2023 | |
Facioscapulohumeral muscular dystrophy: the road to targeted therapies.
Tihaya MS, Mul K, Balog J, de Greef JC, Tapscott SJ, Tawil R, Statland JM, van der Maarel SM |
Nature reviews. Neurology | 2023 |
Non-myogenic mesenchymal cells contribute to muscle degeneration in facioscapulohumeral muscular dystrophy patients.
Di Pietro L, Giacalone F, Ragozzino E, Saccone V, Tiberio F, De Bardi M, Picozza M, Borsellino G, Lattanzi W, Guadagni E, Bortolani S, Tasca G, Ricci E, Parolini O |
Cell Death and Disease | 2022 |
Analysis of DUX4 Expression in Bone Marrow and Re-Discussion of DUX4 Function in the Health and Disease.
Hangul C, Tokta O, Karauzum SB, Akkaya B, Yildirim H, Kupesiz FT, Akinel AN |
2022 | |
Systemic antisense therapeutics inhibiting DUX4 expression ameliorates FSHD-like pathology in an FSHD mouse model
N Lu-Nguyen, A Malerba, S Herath, G Dickson, L Popplewell |
Human Molecular Genetics | 2021 |
Pathomechanisms and biomarkers in facioscapulohumeral muscular dystrophy: roles of DUX4 and PAX7
CR Banerji, PS Zammit |
EMBO Molecular Medicine | 2021 |
Facioscapulohumeral muscular dystrophy: genetics, gene activation and downstream signalling with regard to recent therapeutic approaches: an update
T Schätzl, L Kaiser, HP Deigner |
Orphanet Journal of Rare Diseases | 2021 |
A Network Medicine Approach for Drug Repurposing in Duchenne Muscular Dystrophy
SD Lombardo, MS Basile, R Ciurleo, A Bramanti, A Arcidiacono, K Mangano, P Bramanti, F Nicoletti, P Fagone |
Genes & development | 2021 |
Human miRNA miR-675 inhibits DUX4 expression and may be exploited as a potential treatment for Facioscapulohumeral muscular dystrophy
NY Saad, M Al-Kharsan, SE Garwick-Coppens, GA Chermahini, MA Harper, A Palo, RL Boudreau, SQ Harper |
Nature Communications | 2021 |
Random forest: random results or meaningful insights for patients with facioscapulohumeral muscular dystrophy?
LN Alfano, T Mozaffar |
Brain | 2021 |
Predictors of functional outcomes in patients with facioscapulohumeral muscular dystrophy
NK Katz, J Hogan, R Delbango, C Cernik, R Tawil, JM Statland |
Brain | 2021 |
DUX4 Role in Normal Physiology and in FSHD Muscular Dystrophy
E Mocciaro, V Runfola, P Ghezzi, M Pannese, D Gabellini |
Cells | 2021 |
Promising Perspective to Facioscapulohumeral Muscular Dystrophy Treatment: Nutraceuticals and Phytochemicals.
Hangül C, Karaüzüm SB, Akkol EK, Demir-Dora D, Çetin Z, Saygılı Eİ, Evcili G, Sobarzo-Sánchez E |
Current neuropharmacology | 2021 |
DUX4 Signalling in the Pathogenesis of Facioscapulohumeral Muscular Dystrophy
KR Lim, Q Nguyen, T Yokota |
International journal of molecular sciences | 2020 |
Consequences of epigenetic derepression in facioscapulohumeral muscular dystrophy
A Greco, R Goossens, B Engelen, SM Maarel |
Clinical Genetics | 2020 |
Estrogens Counteract Platinum-Chemosensitivity by Modifying the Subcellular Localization of MDM4
R Lucà, G di Blasio, D Gallo, V Monteleone, I Manni, L Fici, M Buttarelli, G Ciolli, M Pellegrino, E Teveroni, S Maiullari, A Ciucci, A Apollo, F Mancini, MP Gentileschi, GF Zannoni, A Pontecorvi, G Scambia, F Moretti |
Cancers | 2019 |
ADCK2 Haploinsufficiency Reduces Mitochondrial Lipid Oxidation and Causes Myopathy Associated with CoQ Deficiency
VF, Schaefer, NE, SO, HC, Guerra, Cascajo, SC, Horvath, Siendones, Jou, Casado, Gutiérrez, BC, LL, FA, CR, RA, Matté, Ribes, PS, DT, Francesco, Aon, Bernier, Salviati, Artuch, Cabo, Jackson, Navas |
Journal of Clinical Medicine | 2019 |
Clinically Advanced p38 Inhibitors Suppress DUX4 Expression in Cellular and Animal Models of Facioscapulohumeral Muscular Dystrophy
J Oliva, S Galasinski, A Richey, AE Campbell, MJ Meyers, N Modi, JW Zhong, R Tawil, SJ Tapscott, FM Sverdrup |
The Journal of pharmacology and experimental therapeutics | 2019 |
FSHD1 and FSHD2 form a disease continuum
S Sacconi, A Briand-Suleau, M Gros, C Baudoin, RJ Lemmers, S Rondeau, N Lagha, P Nigumann, C Cambieri, A Puma, F Chapon, T Stojkovic, C Vial, F Bouhour, M Cao, E Pegoraro, P Petiot, A Behin, B Marc, B Eymard, A Echaniz-Laguna, P Laforet, L Salviati, M Jeanpierre, G Cristofari, SM van der Maarel |
Neurology | 2019 |
Muscle metabolism and atrophy: let’s talk about sex
ME Rosa-Caldwell, NP Greene |
Biology of sex differences | 2019 |
Patient-Reported Symptoms in Facioscapulohumeral Muscular Dystrophy (PRISM-FSHD)
J Hamel, N Johnson, R Tawil, WB Martens, N Dilek, MP McDermott, C Heatwole |
Neurology | 2019 |
Tracking muscle wasting and disease activity in facioscapulohumeral muscular dystrophy by qualitative longitudinal imaging
M Monforte, F Laschena, P Ottaviani, MR Bagnato, A Pichiecchio, G Tasca, E Ricci |
Journal of Cachexia, Sarcopenia and Muscle | 2019 |
Exciting perspectives for Translational Myology in the Abstracts of the 2018Spring PaduaMuscleDays: Giovanni Salviati Memorial – Chapter II - Abstracts of March 15, 2018
U Carraro |
European Journal of Translational Myology | 2018 |
Functional domains of the FSHD-associated DUX4 protein
H Mitsuhashi, S Ishimaru, S Homma, B Yu, Y Honma, ML Beermann, JB Miller |
Biology Open | 2018 |
A patient-derived iPSC model revealed oxidative stress increases facioscapulohumeral muscular dystrophy-causative DUX4
M Sasaki-Honda, T Jonouchi, M Arai, A Hotta, S Mitsuhashi, I Nishino, R Matsuda, H Sakurai |
Human Molecular Genetics | 2018 |
Facioscapulohumeral Muscular Dystrophy: Update on Pathogenesis and Future Treatments
J Hamel, R Tawil |
Neurotherapeutics | 2018 |